September industry news: investigational gene therapy demonstrates motor function improvement in patients with Parkinson’s
AIdriven research projecting new drug developments, Pharmaceutical technology, Innovating medicine with advanced predictive analytics
This month our industry news round-up includes announcements on an investigational gene therapy for advanced Parkinson’s disease, an inhaled drug for acute migraine, Libervant™ (diazepam) Buccal Film for seizure clusters, new MAVENCLAD® (cladribine tablets) data for relapsing multiple sclerosis, ATA188 data for progressive multiple sclerosis and satralizumab in neuromyelitis optica spectrum disorder. Take a look a September’s headlines below: Investigational gene therapy demonstrates motor function improvement in patients with Parkinson’s Inhaled drug for acute migraine fails Phase III clinical trial US FDA rejects oral diazepam-based drug for management of seizure clusters New MAVENCLAD® data highlights rapid onset of action for...
